The role of therapies in the treatment of small renal masses

To analize the current role of target therapies in the treatment of small renal masses. We performed a bibliographic review on the effect of target therapies on primary renal tumor, including our initial experience with two cases of small renal tumor in single kidneys treated with sunitinib. There i...

Full description

Saved in:

Bibliographic Details
Published in:	Archivos españoles de urología Vol. 66; no. 1; pp. 186 - 191
Main Authors:	Vázquez-Alonso, Fernando, Puche-Sanz, Ignacio, Flores Martín, José, Martínez-Morcillo, Antonio, Vicente-Prados, Francisco Javier, Cózar-Olmo, José Manuel
Format:	Journal Article
Language:	Spanish
Published:	Spain 01-01-2013
Subjects:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - surgery Carcinoma, Small Cell - therapy Combined Modality Therapy Female Humans Indoles - adverse effects Indoles - therapeutic use Kidney Neoplasms - drug therapy Kidney Neoplasms - surgery Kidney Neoplasms - therapy Middle Aged Pyrimidines - therapeutic use Pyrroles - adverse effects Pyrroles - therapeutic use Sulfonamides - therapeutic use
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To analize the current role of target therapies in the treatment of small renal masses. We performed a bibliographic review on the effect of target therapies on primary renal tumor, including our initial experience with two cases of small renal tumor in single kidneys treated with sunitinib. There is very limited experience with target therapies, being possible to use them, as the reviewed literature shows, to increase safety in nephron sparing surgery or tissue ablation technique, or as the treatment for small renal tumors in patients with single kidney in whom nephron sparing surgery is not feasible. Of our two cases with small renal tumors in patients with single kidney, the first case has had complete response to sunitinib after 21 months of follow up, and the second has had tumor stabilization after 33 months of follow up, shifting from sunitinib to pazopanib due to intolerance. The indication of target therapies in the treatment of metastatic renal cancer could be expanded. These therapies could be useful in localized small renal cancer and, although experience with this indication is limited, results are promising.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Review-3 content type line 23 ObjectType-Case Study-5 ObjectType-Feature-1 ObjectType-Report-4
ISSN:	1576-8260